Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 1,101–1,139 of 1,139
Groothof, D., Erler, N. S., & Bakker, S. J. L. (2026) · Open Research Europe · doi:10.12688/openreseurope.20428.2 · Cited by 1
Feraco, A., Camajani, E., Muscogiuri, G., Barrea, L., Colao, A., & Caprio, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00695-7 · Cited by 2
“Emerging medications, such as the triple agonist retatrutide, have achieved even greater reductions in phase 2 studies, and combination therapies suggest synergistic effects on appetite and energy homeostasis [ 46, 47].”
The Pathophysiology of Obesity and Obesity-Related Diseases
Bozadjieva-Kramer, N., & O’Rourke, R. W. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_6
Kaltsas, A., Gkioxaris, V., Giannakas, T., Zachariou, A., Dimitriadis, F., Sofikitis, N., & Chrisofos, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187313
“Fourth, agent-specific analyses are required for the dual GIP/GLP-1 receptor agonist tirzepatide and for oral formulations and multi-receptor agonists [2,37–39].”
Editorial: Effects of nonpharmacological interventions on HbA1c variability and glycemic control
Felício, J. S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1482920
“…fi cient drugs for the control of DM, including Retatrutide, an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors, which was shown in a recent phase 2 clinical trial to be able to reduce up to 24.2% of the weight of research participants (9).”
BackgroundInfluentialPresent State and Perspectives of Type 2 Diabetes Management
Azeez, T. A. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1002447 · Cited by 1
Lifestyle Interventions for the Prevention of Type 2 Diabetes Mellitus
Henson, J. J., Davies, M. J., Greaves, C., Khunti, K., & Yates, T. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00003-3
Azlan, A. H. M., Subramaniyan, V., Ong, L. C., Dawe, G. S., & Ravi, R. N. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100741
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Pharmacological management of obesity: Current landscape and emerging therapies
Atal, S., Agrawal, C., Gupta, R., & Sadasivam, B. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_37_26
“[33] Currently, TRIUMPH phase 3 studies and a head‑to‑head comparison with tirzepatide ( TRIUMPH 5 ) are ongoing, which will determine whether retatrutide sets a new benchmark for nonsurgical weight loss or not.”
5. Weight control in type 2 diabetes management
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112149
Medikamente zur Behandlung von Essstörungen und Adipositas
Himmerich, H. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_9
Incretin-Based Therapies and the Associated Impact on Bone Health
Łupina, K., Bronowski, M., Dardzińska, N., Jaskulska, P., Nowak, A., Romac, A., RÓŻAŃSKI, P., & Janczura, J. (2026) · International Journal of Pharmacology · doi:10.31083/ijp53550
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease
Kumar, S., Macedo, M. P., Roden, M., & Kashyap, S. R. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.003
Treatment with bariatric surgery in patients with osteogenesis imperfecta and severe obesity
Hald, J. D., Hald, A.-M. W., Harsløf, T., Langdahl, B. L., & Bruun, J. M. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101811
Петунина, Н. А., Гончарова, Е. В., Ханмирзоева, С. Э., Воробьев, А. В., Писарев, В. В., & Кузина, И. А. (2026) · Axis of endocrinology · doi:10.46393/30337380_2026_2_34-40
González‐Fierro, A., Chávez-Blanco, A. D., Domínguez-Gómez, G., Romo‐Pérez, A., Pastrana-Peralta, P., Gutiérrez-Delgado, F., Kast, R. E., Correa‐Basurto, J., Algara, A. L. C., & Dueñas‐González, A. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2682866
“…oncology, such as the triple-target drug candidate (agonist of Glucalon-Like Peptide-1 (GLP-1), Gastric Inhibitory Polypeptide (GIP), and glucagon receptors) retatrutide that is being developed for diabetes and obesity [49,50], and the dual agonist for GLP-1 and GIP tirzepatide for diabetes [51].”
Obesity: a disease of the ponderostat and the regulation of energy balance
Buscemi, S., Buscemi, C., Colombrita, P., Randazzo, C., Barile, A. M., & Arnaldi, G. (2025) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-025-01790-9 · Cited by 2
당뇨병 치료의 진화: 관해를 향해가는 혁신적 약물치료와 첨단 관리기기의 결합
Choi, J. H., & Moon, M. K. (2024) · Public Health Weekly Report · doi:10.56786/phwr.2024.17.44.4
“0 % in patients with type 2 diabetes [ 41 ] and facilitated weight loss of over 20 % in those with obesity, along with improvements in MASLD [ 42 , 43 ].”
Anti-Obesity Drugs: The Rising Significance of GLP-1Agonist, Tirzepatide
Agrawal, P. K., & Garg, R. (2026) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_259_25
“[3] Conclusion GLP‑1‑based therapies represent a paradigm shift in the management of obesity.”
Peptide‐small Molecule Drug Conjugates for Cancer, Metabolic Diseases, and Beyond
He, R., Singh, S., & Mezo, A. R. (2025) · Peptide Science · doi:10.1002/9781119824701.ch12 · Cited by 1
López, G. P. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107122 · Cited by 2
Bruner, W. S., Grant, S. F., & McCormack, S. E. (2024) · Wiley eBooks · doi:10.1002/9780470015902.a0029841
Cardiovascular effects of incretin receptor agonists: beyond glycemic control
Ravić, M. P., Srejovic, I. M., Milosavljević, I., Novakovic, J. N., Jakovljević, V., Vučićević, K., Petrovic, D., & Muric, M. D. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0184
Chaturvedi, R., Singh, K., Chakole, R., Yadav, B. K., Dhameliya, J., & Joshi, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1969433 · Cited by 2
Ismaiel, A., & Dumitrascu, D. L. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102146
Impact of Obesity and Its Treatment on Inflammatory Bowel Disease Outcomes: A Narrative Review
Redavid, C., Pirro, P., Bertin, L., & Savarino, E. V. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17040057
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
Molecular signaling networks that connect tissue dysfunction to systemic insulin resistance
Mir, R., Algehainy, N. A., Jalal, M. M., Altayar, M. A., Almotairi, R., Tayeb, F. J., Bedaiwi, R. I., Altemani, F. H., Almasoudi, K. S., Albalawi, I. A., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1952238
Novel Anti-Obesity Drugs: Pharmacokinetics, Pharmacodynamics, and Precision Dosing
Badawoud, A. M., Zaafar, D. K., AlRasheed, H. A., Aldossary, K. M., Alsharif, A. A., & Alsaleh, N. A. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00482-x
“The extent to which glucagon-receptor activation increases human energy expenditure or contributes independently to weight loss remains under investigation [ 21].”
Buzzi, R. M., & Huber, L. C. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-276106
Yagudina, R. I., & Tsapko, D. S. (2026) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2026-14-3-263-277
Sukurica, E., Sengul, G. F., & Uysal, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71422 · Cited by 2
Zhou, Z., Cheng, Z., Jin, P., Yang, G., Wang, H., Shi, B., Dong, Q., Shi, X., Shi, X., Shu, H., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.09.021 · Cited by 1
Paccou, J., Rolvien, T., Hauser, B., Sølling, A. S., Anastasilakis, A. D., & Lems, W. F. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261460301
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Brogaard, E., & Thomsen, S. F. (2026) · Targets · doi:10.3390/targets4040033
Santos, G. V. D., Nascimento, E. D. S. R. D., Carvalho, R. O. V., Teixeira, M. S., Bezerra, P. T. M., Vieira, L. H. S., Bezerra, I. P., Salvadego, M. A. L. D. O., Alexandre, B. G. F., Nascimento, S. B. D., et al. (2026) · Pathways to Health: Innovations and Approaches in Health Sciences - 2nd Edition · doi:10.56238/sevened2026.020-072
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.